Comparison of Treatment Outcomes Between Gemcitabine With Nab-Paclitaxel and Modified FOLFIRINOX for First-Line Chemotherapy in Metastatic and Recurrent Pancreatic Cancer: Propensity Score Matching. Issue 4 (April 2021)

• Record Type: Journal Article
• Authors: Mie, Takafumi; Sasaki, Takashi; Takeda, Tsuyoshi; Fukuda, Koshiro; Furukawa, Takaaki; Yamada, Yuto; Kasuga, Akiyoshi; Matsuyama, Masato; Ozaka, Masato; Sasahira, Naoki
• Is Part Of: Pancreas. Volume 50:Issue 4(2021)
• Publication Date: 2021-04
• Subjects: pancreatic cancer -- metastatic -- gemcitabine with nab-paclitaxel -- FOLFIRINOX -- propensity score matching -- AEs - adverse events, CA 19-9 - carbohydrate antigen 19-9, CEA - carcinoembryonic antigen, CI - confidence interval, FFX - FOLFIRINOX, GnP - gemcitabine with nab-paclitaxel, HR - hazard ratio, mFFX - modified FOLFIRINOX, OS - overall survival, PC - pancreatic cancer, PFS - progression-free survival, PS - performance status, UGT - uridine diphosphate glucuronosyltransferase; Pancreas -- Diseases -- Periodicals; Pancreas -- Periodicals; Neuroendocrine tumors -- Periodicals; 616.37005
• DOI: 10.1097/MPA.0000000000001801
• Languages: English
• ISSNs: 0885-3177

Abstract

Abstract : Objectives: To compare the treatment outcomes of gemcitabine with nab-paclitaxel (GnP) and modified FOLFIRINOX (mFFX; a combination of fluorouracil, leucovorin, irinotecan, and oxaliplatin) for metastatic pancreatic cancer. Methods: We retrospectively analyzed consecutive patients with metastatic or recurrent pancreatic cancer treated with GnP or mFFX as the first-line chemotherapy between March 2014 and December 2019 in our hospital. Treatment outcomes were compared using propensity score matching to adjust for age, sex, performance status, carcinoembryonic antigen levels, carbohydrate antigen 19-9 levels, and disease status (metastatic or recurrent). Results: Five hundred sixty-eight patients were included (GnP/mFFX, 456/112). After propensity score matching, 218 patients were extracted. The median age was around 61 years, and the proportion of performance status 0 was approximately 90%. The median overall survival values were 14.6 and 15.5 months ( P = 0.45), and the median progression-free survival was 7.4 months ( P = 0.53) for GnP and mFFX, respectively. The disease control rates were higher in the GnP group (82.6% vs 67.9%, P = 0.02). In nonhematologic adverse events, grade 3/4 anorexia and diarrhea occurred significantly more frequently in the mFFX group. Conclusions: Gemcitabine with nab-paclitaxel had a higher disease control rate and lower rates of severe anorexia and diarrhea in our propensity-matched population.